Cancer stem cell studies may improve understanding of tumor pathophysiology and identify more effective strategies for cancer treatment. In a variety of organisms, Piwil2 has been implicated in multiple roles including stem cell self-renewal, RNA silencing, and translational control. In this study, we documented specific expression of the stem cell protein Piwil2 in breast cancer with predominant expression in breast cancer stem cells. In patients who were evaluated, we determined that 90% of invasive carcinomas and 81% of carcinomas in situ exhibited highest expression of Piwil2. In breast cancer cells, Piwil2 silencing suppressed the expression of signal transducer and activator of transcription 3, a pivotal regulator of Bcl-X L and cyclin D1, whose downregulation paralleled a reduction in cell proliferation and survival. Our findings define Piwil2 and its effector signaling pathways as key factors in the proliferation and survival of breast cancer stem cells. Cancer Res; 70(11); OF1-11. ©2010 AACR.
Introduction
Considerable evidence is accumulating that tumor initiation and growth, like that of breast tumors, are modulated by a distinct population of cells within the tumors known as cancer stem cells (refs. 1-3) . As an example, a subset of cells, highly expressing CD44 but low or devoid of CD24 (CD44 + CD24 −/low ), were isolated from pleural effusion, which were derived from malignant human breast cancer. These cells showed a high level of tumorigenicity when injected into nonobese diabetic/severe combined immune deficiency mice, yet manifesting the characteristics of stem cells such as self-renewal and heterogeneous differentiation (3) . Furthermore, another study indicated that individual cells from a CD44 + CD24 −/low subset of cells derived from primary breast tumors were able to give rise to mammospheres, hence confirming their stem cell features (4) . Mammospheres are defined as masses of nonadherent spherical cells that are grown in a specific culture condition and are rich in mammary stem/progenitor cells (5) . Stem and progenitor cells are of great interest in cancer research because it is believed that these cells are the initial targets for malignant transformation. The emergence of cancer stem cell theory and the proposition of trophoblastic theory of cancer affiliating it to germ cell-derived trophoblastic tissues (6) , along with the evidence for an association between gametogenesis and cancer development, were the main reasons that stimulated our investigation of the expression pattern of the germline stem cell protein Piwil2 in breast cancer stem cells. Piwil2 belongs to the piwi gene family, the members of which are characterized by conserved PAZ and PIWI domains and play crucial roles in the self-renewal mechanism of stem and germ cells, RNA silencing, and translational regulation in different organisms during evolution (7) . Previously, we and other groups showed that Piwil1 and Piwil2 are specifically expressed in premeiotic germ cells but are also aberrantly expressed in different tumors, including breast cancer (8) (9) (10) (11) .
The central focus of this study is the investigation of the roles of Piwil2 in breast cancer stem cells. We also analyzed the molecular pathway of Piwil2 in breast cancer and its role in proliferation and apoptosis of breast cancer cells. These analyses showed that Piwil2 is predominantly expressed in breast cancer cells and Piwil2 is essential for their proliferation and escape from apoptosis.
Materials and Methods

Plasmid construction
For generation of human Piwil2 promoter-EGFP Express gene construct, 2 kb of the upstream region of human Piwil2 gene were amplified from genomic DNA and cloned upstream to the coding region of the enhanced green fluorescence protein (EGFP) gene in pEGFP-1 vector (BD Biosciences Clontech) harboring the neomycin resistance gene under the control of SV40 early enhancer. The HSV-TK gene was cloned downstream of the human Piwil2 promoter construct (hPiwil2 promoter-HSV-TK). The final constructs were sequenced at cloned regions.
Cell culture
The human breast cancer cell line MDA-MB-231 and the nontumorigenic epithelial cell line MCF12A were obtained from the American Type Culture Collection (ATCC) and cultured according to the manufacturer's instructions. To transfect the cells, an incubation of 30 minutes at room temperature was done for a mixture of 4 μg of vector, 100 μL of serum-free medium, and 8 μg of Clonfectin. The cells were incubated with this mixture for 4 hours in a 5% CO 2 incubator before being washed with PBS. The cells were then further cultured in expansion medium for 3 days. The cell phenotypes were analyzed using a fluorescence microscope (Olympus BX60) after 48 hours.
Isolation of breast cancer stem cells
Single-cell suspensions were generated using trypsin (Invitrogen). Single cells were suspended in PBS at a concentration of 1 × 10 6 /mL. Cells were washed again three times. Cells (1 × 10 6 ) were incubated with anti-CD44-FITC and anti-CD24-phycoerythrin antibodies (BD Bioscience) at 2 μg/mL (1:10) in the dark, on ice, for 60 minutes, washed twice with cold PBS, then resuspended in PBS (0.5 mL) for flow cytometry analyses using a FACSCalibur instrument (BD Biosciences).
Mammospheres (potent breast cancer stem-like progenitor cells) were isolated as nonadherent cells from the MCF7 breast cancer cell line (ATCC) and cultured in Mammary Epithelial Growth Medium (Cambrex), supplemented with 10 ng/mL basic fibroblast growth factor, 10 ng/mL epithelial growth factor, and heparin (4) . When analyzed with a flow cytometer, mammospheres were CD44 + /CD24 −/low .
Briefly, cells were mixed with antibody against CD24 and CD44 (BD Pharmingen), incubated for 15 minutes in the dark, and washed with PBS containing 1% FCS. After centrifugation at 2,500 × g for 5 minutes, the pellet was immediately resuspended in PBS containing 1% FCS and processed for flow cytometry analysis (Becton Dickinson).
Northern blot hybridization
Human MTN Blot II was purchased from Clontech (2 μg of polyadenylated RNA per lane). Partial cDNA fragments of the Piwil2 and β-actin genes were amplified by reverse transcription-PCR (RT-PCR). After confirming the sequence, PCR fragments were labeled with 32 P and used as probes for hybridization. The membrane was stripped and rehybridized with a β-actin probe to prove RNA integrity and for comparison of RNA loading amount.
RNA preparation and RT-PCR analysis
RNeasy Mini kit (QIAGEN) was used to extract total RNA from human breast cancer cell lines (MDA-MB-231 and MCF7) based on the manufacturer's instructions. Human total RNAs from heart, lung, and testis were purchased from BD Biosciences (BD Clontech). The preparation of cDNA was done using 5 μg of RNA programmed with reverse transcription kit (Invitrogen), followed by amplification reaction using the following primers: Piwil2 (5′-CAGGCAGAGGC-CATGTATTT-3′, 5′-AACATGCCGACCTCATGCT-3′), Bcl-X L (5′-ATCAATGGCAACCCATCCTG-3′, 5′-GTAAGTGGCCA-TCCAAGCTG-3′), cyclin D1 (5′-TGCATGTTCGTGGCC-TCTAA-3′, 5′-CAGTCTGGGTCACACTTGAT-3′), Akt (5′-AC-GCCATGAAGATCCTC AAG-3′, 5′-TTAATGTGCCCGTC-CTTGTC-3′), Stat3 (5′-ATTGACCAGCAGTATA GCCG-3′, 5′-TTCCAGCTGCTGCATCTTCT-3′), GAPDH (5′-CCAGCAAG AGCACAAGAGGAAGAG-3′, 5′-AGCACGGGATACTTTATTA-GAT G-3′), and β-actin (5′-CCTGAACCCCAAGGCCAACCGC-GAG-3′, 5′-TGGGCACAGTGTGGGT GACCCCGTC-3′).
Apoptosis assay
The BD ApoAlert DNA Fragmentation Assay Kit (BD Clontech) was used to assess the apoptosis level on the basis of the fluorescent measurement of apoptosis-induced DNA fragmentation. MDA-MB-231 cells transfected with Piwil2 siRNA were prepared for apoptosis assay according to the manufacturer's manual, and the apoptotic cells were visualized and quantified under a fluorescence microscope.
Immunocytochemistry and immunohistochemistry
MDA-MB-231 cells expressing Piwil2 siRNA were cultured on chamber slides (FALCON) up to 50% to 60% confluence before being fixed with 4% paraformaldehyde. The cells were then immersed three times in PBS, followed by incubation with a monoclonal anti-Piwil2 antibody produced in our laboratory in a dilution of 1:200.
Breast tissue immunohistochemistry was done by the 3,3′-diaminobenzidine method with a heat-induced antigen retrieval step in a steamer for 40 minutes. After deparaffinization and rehydration, the slides were treated with 3% H 2 O 2 for 30 minutes and 10% bovine serum albumin/5% FCS for 15 minutes. Slides were incubated for 1 hour at room temperature with monoclonal antihuman Piwil2 antibody (1:200).
Oct4 and Nanog immunostaining was accomplished with polyclonal anti-Oct4 and anti-Nanog antibodies (Abcam), both diluted at 1:200.
4′,6-Diamidino-2-phenylindole (VECTASHIELD Mounting Medium with DAPI, Vector Labs) was diluted in 0.1 mol/L PBS and used to counterstain cell nuclei in immunostaining to count the cells and evaluate gross morphology of cells.
siRNA experiments
Piwil2 sense and antisense siRNAs (Invitrogen siRNA) as well as those of Luciferase (Eurogentec) as a negative control were introduced at 80 nmol/L concentration into 2.0 × 10 5 MDA-MB-231 cells cultured in each well of a six-well plate. Lipofectamine 2000 (Invitrogen) was used as a cationic carrier for siRNA delivery to the cells, and the procedure was followed according to the manufacturer's manual. The cells were treated with siRNAs for 8 hours before replacing with fresh growth medium and culturing the cells for 48 hours.
Total RNAs were extracted from the transfected cells at 0, 24, and 48 hours after siRNA knockdown/transfection. The apoptotic assay was done on the cells, which were knocked down for 24 hours. This experiment was done in triplicates, and the siRNA sequences were as follows: Piwil2 sense, 5′-GGA-UCUAUUCUCUAUCUGCCUGUUA-3′; Piwil2 antisense, 5′-UAACAGGCAGAUAGAGAAUAGAUCC-3′; Luciferase sense, 5′-CGUACGCGGAAUACUUCGAdTdT-3′; and Luciferase antisense, 5′-UCGAAGUA UUCCGCGUACGdTdT-3′.
In vitro ganciclovir treatment
Cells were transfected with hPiwil2 promoter-HSV-TK DNA, and G418-resistant cells were selected. These cells were plated at 10 3 per well in 96-well plates and subsequently treated with various concentrations (0, 2, 5, 20, 50, 100, and 150 μg/mL) of ganciclovir. After 7 days, viable cell numbers in each well were measured with Vi-CELL Series Cell Viability Analyzers (Beckman Coulter, Inc.).
Clinical samples
Breast carcinomas without metastatic spread (7 ductal carcinoma, 1 lobular carcinoma, 2 ductal and lobular carcinoma, and 1 medullary carcinoma) were used for immunohistologic and RNA analysis. Additionally, specimens of 20 breast cancer patients [infiltrating lobular carcinoma (n = 4), infiltrating ductal carcinoma (n = 9), tubular carcinoma (n = 1), medullary carcinoma (n = 1), mixed lobular and ductal carcinoma (n = 5)] including all above-mentioned breast cancer patients and 10 samples of benign breast lesions (5 fibrocystic mastopathy and 5 fibroadenomas) were acquired from the Department of Pathology, Universitaetsmedizin Göttingen.
Tissue microarray
Immunohistochemistry was done using a tissue microarray of benign and malignant breast biopsies. All materials were used in accordance with approval granted by the Sunderland Local Research Ethics Committee, REC reference no. 04/Q0904/61. The average core loss was 28%, and the final study included 149 biopsies, comprising 8 benign, 16 carcinomas in situ, and 125 invasive carcinomas. Antigen retrieval was achieved by heat-induced epitope retrieval for 2 minutes in 10 mmol/L citric acid buffer (pH 6.0). Sections were immunostained with rabbit polyclonal antibody against Piwil2, at a dilution of 1: 200, following optimization of antibody dilution on composite tissue blocks. In each batch, sections with positive staining were included, and for the negative controls the primary antibody was substituted by PBS. Piwil2 expression was scored blindly by intensity of staining in each biopsy core as being absent (0), weak (+), moderate (++), or strong (+++). Images were captured using an Aperio ScanScope CS digital slide scanning system. Subsequent images were analyzed using Aperio Imagescope and SpectrumPlus software.
Gene array analysis
We used a recently described cohort of 782 node-negative breast cancer patients without a history of chemotherapy (12, 13) . The cohort consists of 194 patients from the Mainz (12), 286 patients from the Rotterdam (14) , and 302 patients from the Transbig cohorts (15, 16) . Gene array analysis, normalization of expression data, and statistical analysis were done as described by Schmidt and colleagues (12) .
Results
Piwil2 is aberrantly expressed in breast cancer cells and tissues
Previously, it has been shown that human Piwil2 is expressed specifically in testis. To confirm this, we analyzed its expression through Northern blot analysis and immunohistostaining on human testicular sections. Specific expression of Piwil2 in testis could be observed as a single band of 3.6 kb in Northern blot analysis (Fig. 1A) . In testis, expression of Piwil2 was found in premeiotic and early meiotic germ cells (Fig. 1B) . In breast cancer tissue, expression of Piwil2 was detected in 17 of 18 tissues by RT-PCR analysis (Fig. 1C) . This expression pattern could be confirmed in ductal and lobular cancer tissues by immunostaining analysis (Fig. 1B) . No expression was apparent in fibroadenoma tissues (Fig. 1B) . Whereas expression of Piwil2 was found in malignant breast cancer cell lines, no expression was evident in the nontumorigenic epithelial cell line MCF12A (Fig. 1B  and D) .
We next analyzed the expression of Piwil2 in breast cancer patients using an RNA array consisting of node-negative patients derived from the Mainz, Rotterdam, and Transbig cohorts (12) . Piwil2 expression was detectable in all carcinomas, wherein the majority of patients showed a Gaussian distribution ( Fig. 2A ) and a small fraction of patients expressed Piwil2 at very high levels. Piwil2 expression was not associated with histologic grade (P = 0.580), stage (P = 0.580), hormone receptor status (P = 0.718), erbB2 status (P = 0.434), or age of patients (P = 0.450). Piwil2 expression was not associated with metastasis-free interval in Kaplan-Meier analysis (Supplementary Fig. S1 ) nor in univariate as well as multivariate Cox analysis (data not shown).
To confirm this result at the protein level, we examined the expression of Piwil2 in human breast cancer using a tissue microarray that represented benign, in situ, and invasive disease. Of the 149 patients that could be evaluated for Piwil2 protein expression, the highest expression was noted in invasive carcinomas (Supplementary Table S1 ). Piwil2 expression was detected in 90% of invasive carcinomas and 81% of carcinomas in situ. Moderate to strong staining (scores of +2 and +3) was apparent in 50% of invasive carcinomas and 25% of carcinomas in situ. There was no statistical difference in the expression of Piwil2 between invasive carcinoma and carcinoma in situ or ductal and lobular carcinoma. The staining in the neoplastic cells was predominantly cytoplasmic, either diffuse or in clusters ( Fig. 2B and C) , but there were some cases showing nuclear expression (data not shown). Interestingly, we observed expression of Piwil2 in nonneoplastic cells adjacent to the neoplasm, in both nuclei and cytoplasm (Fig. 2D) . A high resolution of this figure is shown in Supplementary Fig. S2 . Expression of Piwil2 did not correlate with estrogen receptor or progesterone receptor status or with expression of c-erbB2 or epidermal growth factor receptor. Furthermore, no statistical correlation was seen with local stage or metastases for Piwil2 expression in either multivariant or univariant analyses.
These data suggest that Piwil2 might play a role in the early steps of breast cancer tumorigenesis regardless of the stages and grades of breast tumor.
Piwil2 is predominantly expressed in breast cancer stem cells
Putative cancer stem cells were initially observed in breast cancer among the other human carcinomas as a distinct subset of cells (3) . To evaluate the expression pattern of Piwil2 in breast cancer stem cells, we isolated this cell population from MCF7 and MDA-MB-231 cell lines (MCF7 in Fig. 3A) . This cell population forms mammospheres, which is characteristic for breast cancer stem cells (MCF7 in Fig. 3B) . A predominant expression of Piwil2 was found in the CD44 + / CD24 −/low fraction isolated from both cell lines (Fig. 3C) using semiquantitative RT-PCR analysis. To confirm this result, isolated cancer stem cells were subjected to immunocytochemistry using anti-Piwil2 antibody. Most CD44 + /CD24 −/low cells were found to express Piwil2 (86%), whereas only 12% of total cancer cells displayed Piwil2 expression, indicating predominant expression of Piwil2 in breast cancer stem cells (Fig. 3D) . Cancer stem cells show traits similar to those of normal stem cells. It was found that histologically poorly differentiated tumors show preferential overexpression of genes, including Oct4 and Nanog, normally enriched in embryonic stem cells (17) . To analyze the expression pattern of Oct4 and Nanog in Piwil2-expressing breast cancer cells, we constructed a fusion gene harboring a 2-kb 5′ flanking region of the human Piwil2 gene linked to the coding region of EGFP and established cell lines with stable integration of this gene (Fig. 4A) . A fraction of breast cancer cells expressed EGFP Figure 1 . Expression pattern of Piwil2 in normal and cancerous tissues and cells. A, Northern blot analysis was done with mRNA isolated from spleen, thymus, prostate, testis, ovary, small intestine, colon, peripheral blood, and lymphocytes. A specific 3.6-kb transcript was found in human testicular RNA. The blot was rehybridized with β-actin probe to assess RNA integrity. B, immunostaining using Piwil2 antibody. Positive staining was obtained in premeiotic germ cells in testis, in ductal and lobular carcinoma tissues, and in the cancerous cell line MDA-MB-231. No expression was observed in the normal breast epithelial cell line MCF12A or in fibroadenoma. C, RT-PCR analysis using RNA isolated from breast cancer tissues. Piwil2 transcript could be found in 17 of 18 samples tested (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) . Testicular RNA (19) as a positive control; heart (20) and liver (21) RNAs as negative controls; 22, H 2 O. GAPDH RT-PCR as a control for RNA integrity. D, expression analysis of Piwil2 gene in RNA isolated from different breast cancer cell lines using RT-PCR analysis: MCF7-CIB3 (1), MCF7-MF (2), ZR75B (3), T47D (4), EMF-19 (5), EFF-3 (6), Ca2-83 (7), SKBR-3 (8), HBL-100 (9), MDA-MB-231 (10), MCF12A (11), MCF7 (12), heart (13), testis (14) , and H 2 O (15). GAPDH RT-PCR as a control for RNA integrity. Lee (Fig. 4A) , which could be isolated by fluorescence-activated cell sorting (FACS; Fig. 4B ). EGFP + cells show a similar expression pattern of endogenous Piwil2 as shown by RT-PCR analysis using Piwil2-specific primers (Fig. 4C) . We observed that Oct4 and Nanog are highly expressed in EGFP + cells, indicating the embryonic stem-like identity of the Piwil2 + cell population ( Fig. 4C and D) and supporting the possibility that these genes contribute to the stem celllike phenotype of Piwil2-expressing breast cancer cells.
To examine the stemness of Piwil2-expressing cells on a cellular level, we assessed the colony formation and simultaneous potential for self-renewal and differentiation of this cell population. We sorted Piwil2-EGFP-positive and Piwil2-EGFP-negative cells and plated them on new plates. As shown in Fig. 5A , Piwil2-expressing cells form embryonic stem-like colonies, whereas no colony formation was observed in negative cells. The core stem cell property of stem cells is self-renewal and differentiation potential. After sorting of Piwil2-expressing and nonexpressing cells, these two cell populations were plated in equal amount on new plates. After 2 weeks, Piwil2-EGFP-positive cells were able to produce EGFP-positive (presenting cancer stem cells) and EGFP-negative cells (comprising the bulk), while Piwil2-EGFP-negative cells remained negative (Fig. 5B) as shown by FACS. This result could be confirmed by microscopic analysis of EGFP-positive cells; these cells were able to produce EGFP-positive and EGFP-negative cells after culturing (Supplementary Fig. S3 ). Among Piwil2-expressing cells, two different types of positive cells (GFP + and GFP ++ ) could be detected. Some cells showed very strong EGFP signals (GFP ++ in Supplementary Figs . S4 and S5A) with concomitant mitotic cell division, indicating an increase of Piwil2 expression during cell division (Figs. 3  and 4) .
It was not feasible to perform a loss-of-function siRNA experiment to prove the direct effect of Piwil2 on colony and mammosphere formation due to high transcriptional recovery of Piwil2. Silencing Piwil2 results in downregulation of the Stat3/ Bcl-X L pathway and induction of apoptosis Previously, we showed that Piwil2 induces high-level expression of the antiapoptotic gene Bcl-X L , which was correlated with increased signal transducer and activator of transcription-3 (Stat3) expression (8) . To analyze the antiapoptotic effect of Piwil2 in breast cancer cells, we compared the apoptosis rates of EGFP + and EGFP − cells and found that Piwil2-expressing cells displayed a 5-fold lower apoptosis rate compared with Piwil2-negative cells (2.1% versus 11%; Fig. 6A ). The MDA-MB-231 breast cancer cell line was further analyzed by complementing the apoptotic assays with Piwil2 immunostaining, as a result of which apoptosis and Piwil2 expression were shown to be mutually exclusive in the cancer cells, suggesting an antiapoptotic role for Piwil2 (Fig. 6B) .
To elucidate the antiapoptotic mechanism of Piwil2, its expression was ablated in MDA-MB-231 cells using siRNAs targeting a region in Piwil2 coding sequence. The downregulation of Piwil2 in Piwil2-siRNA-treated cells was confirmed by RT-PCR analysis after 24 hours (Fig. 6C) , whereas no effect was observed in the cells treated with control (Luciferase) siRNAs (Fig. 6C) . Noticeably, an evident decrease in the expression level of some key antiapoptotic and proliferation markers including Stat3, Bcl-X L , and cyclin D1 was detected in MDA-MB-231 cells depleted of Piwil2 (Fig. 6C) , an interesting observation suggesting an upstream role for Piwil2 in the modulation of the Stat3/Bcl-X L /cyclin D1 pathway. To study the involvement of Piwil2/Stat3/Bcl-X L in cellular phenotype, we measured the apoptosis rate in siRNA-treated MDA-MB-231 cells and observed an increase in apoptosis of treated cells (15.1%) compared with control parental cells (3.1%; Fig. 6D ). Furthermore, the causal effect of downregulation of the Piwil2/Stat3/cyclin D1 pathway was shown by a decrease in proliferation rate of siRNA-treated cells (Supplementary Fig. S6 ).
Furthermore, we analyzed which genes correlate with Piwil2 expression by gene array. After restriction to genes with a correlation coefficient of >0.4 and a P value <0.05, after Bonferroni adjustment for multiple testing, 30 genes were identified to correlate with Piwil2. Of these genes, at least 13 are involved in germ cell or in stem cell proliferation and differentiation (Supplementary Table S2) .
Our gene array analysis also included 28 genes that belong to the Bcl family or represent direct protein interaction partners. BOK correlated with Piwil2 not only in the total cohort (P < 0.001; R = 0.37) but also in the individual Mainz (P < 0.001; R = 0.46) and Rotterdam cohorts (P < 0.001; R = 0.37). Bcl-X L correlated with Piwil2 (P < 0.001; R = 0.37) in the Rotterdam subcohort. 
Discussion
Several studies have confirmed the existence of breast cancer stem cells. In this study, we made four novel observations that provide an additional molecular and cellular framework for breast cancer stem cells. These observations are that (a) stem cell-related gene Piwil2 is significantly overexpressed in breast cancer cells and tissue, and this is due to predominant expression in breast cancer stem cell population; (b) Piwil2-expressing cells show higher expression level of markers specific for pluripotent stem cells like Oct4 and Nanog; this cell population shows cellular characteristics of stem cells like colony formation, self-renewal, and differentiation potential; (c) Piwil2 activates pathways related to apoptosis (Stat3/Bcl-X L ) and to proliferation (Stat3/cyclin D1); and (d) inhibition of Piwil2 expression results in increased apoptotic rate and decreased proliferation.
We show that Piwil2 is overexpressed in breast cancer biopsies compared with benign controls. There is an increase in the incidence of Piwil2 expression and the level of expression also increased, highlighting the clinical significance of Piwil2 in breast cancer. However, most, but not all, in situ and invasive carcinoma samples express Piwil2, and this may represent a specific mechanism of disease progression in a discrete cohort. Although there was no correlation with other clinical and pathologic variables, a putative role of Piwil2 in breast cancer progression is suggested by the increased levels of expression in clinical samples. Furthermore, a predominant expression of Piwil2 was observed in the CD44 + / CD24 low/− population, representing breast cancer stem cells (Fig. 3) . In a small fraction (14%) of cancer stem cells, no Piwil2 could be detected and a small fraction (12%) of CD44 − /CD24 + (non cancer stem cells) displayed Piwil2 expression. Previous studies have shown that CD44 and CD24 markers may play a functional role in tumor stage. It was reported that CD44 enhances both invasion and metastasis. This evidence and the fact that Piwil2 promotes CD44 expression in fibroblasts 9 support the hypothesis that Piwil2-expressing cells might be pronounced in more invasive breast cancer. The next step of our research will focus on the correlation between Piwil2 expression level and cancer type, stage, and grade.
Two hypotheses for expression of Piwil2 in breast cancer stem cells might be considered: (a) As Piwil2 is a germ cellspecific protein, the expression of Piwil2 in breast cancer stem cells is an indication of germ cell origin of these cells.
(b) Piwil2 is reactivated in breast cancer stem cells due to cellular transition and transformation of breast cells.
The germ cell origin of cancer was discussed by John Beard in the early 1900s when he noted that a substantial portion of germ cells were subject to migration deviation, hence failing to reach their destination during embryonic development. The outcome therefore would be a population of drifting cells, which could be the cause for cancer initiation later on in abnormal situations. Supportive of this hypothesis was the higher level of Oct4 and Nanog expression in Piwil2-expressing breast cancer cells (Fig. 4) , two markers that are expressed in primordial germ cells and are essential for germ cell maintenance (18) (19) (20) . Other supportive evidence for the germ cell origin of cancer stem cells is the expression of cancer/testis antigen (CTA) in breast and other cancers. Expression of cancer/testis-associated proteins is restricted to germ cells in normal tissues and to different types of malignancies. Recently, it was suggested that CTAs are also implicated in stem cell differentiation pathways (21) . This suggests that the tumor-specific expression of CTAs may be involved in stem cell proliferation and/or differentiation. Chen and colleagues revealed that Piwil2 regulates precancerous stem cells based on environmental factors (22) . According to this hypothesis, expression of Piwil2 as a CTA in breast cancer stem cells is due to the germ cell origin of these cells, which in the inappropriate niche (breast tissue) results in aberrant proliferation and initiation of tumor cells in breast. This hypothesis could be supported by the association of genes specific 9 J.H. Lee, W. Engel, K. Nayernia, unpublished data. Table S2 ).
The second hypothesis explaining the expression of Piwil2 in breast cancer stem cells is based on the cellular transition and transformation of breast cells with subsequent reactivation of germ cell proteins (including Piwil2). This recapitulates the germ cell-specific program in transformed cells, which might activate the neoplastic characteristics, including immortality, invasiveness, hypomethylation, immune evasion, and metastatic capacity. Recently, it was shown that changes in cell phenotype between epithelial and mesenchymal state, defined as epithelial-mesenchymal (EMT) and mesenchymalepithelial transition, have a key role in embryonic development and in the pathogenesis of cancer (23, 24 (25) is an indication for reactivation of Piwil2 after EMT. This is supported by the fact that during embryonic development, groups of epiblast cells undergo EMT to develop mesenchymal stem cells and primordial germ cell progeny with an activated CTA program (including Piwil2) that later becomes inactivated as a result of differentiation (21) . In addition, expression of CTAs is dependent on maintenance of the undifferentiated phenotype in stem cells and cancer cells in which CTAs are expressed and may have lost their ability to differentiate. Higher expression levels of Oct4 and Nanog in Piwil2-expressing breast cancer cells strongly supports this hypothesis (Fig. 4) . Among the activation targets of Nanog, Oct4, and Sox2, genes encoding transcription regulators were most consistently activated in high-grade breast tumors (17) .
EMT and acquisition of cancer stem cell features have also been associated with increased resistance to apoptosis (26) . Murine mammary epithelial cell lines became resistant to apoptosis following EMT. We show that expression of Piwil2 inhibits apoptosis in breast cancer stem cells through activation of the Stat3/Bcl-X L pathway (Fig. 6) . Therefore, Piwil2 might have a role in the apoptotic activity of breast cancer stem cells. Furthermore, it was shown that Stat3 is required for the viability and maintenance of breast cancer stem cells (27) .
The key question in this context is how Piwil2 regulates the expression of genes related to proliferation and apoptosis. One possible mechanism would be Piwil2-mediated gene regulation through small RNA and methylation. In line with this possibility, a subset of small RNA species, termed piwi-interacting RNAs, has been characterized in mammalian testis in which these short RNAs interact with PIWI proteins (Piwil1 and Piwil2) to silence transposon function in the germ cell genome (28) (29) (30) . This implicates piwi-interacting RNAs as specificity determinants of DNA methylation, which is known to be a key component of gene regulation in cancer cells.
Predominant expression of Piwil2 in breast cancer stem cells highlights Piwil2 as a promising target for gene and immune therapy. This possibility can be put into effect by the suicide gene therapy approach, a well-known example of which are the cancer cells expressing the herpes simplex virus thymidine kinase gene (HSVtk) that are selectively targeted by ganciclovir treatment. To evaluate the anticancer cytotoxic effect of HSVtk directed by Piwil2, we generated a construct harboring a 2-kb 5′ flanking region of Piwil2 linked to the coding region of HSVtk (hPiwil2-HSVtk) and established stable cell lines by transfecting MDA-MB-231, as cancer cells, and MCF12A, as normal breast epithelial cells. We next investigated the cytotoxic effect of hPiwil2-HSVtk on cancer cells in response to the prodrug ganciclovir, and we observed that breast cancer cells were extremely susceptible to the targeted cytotoxic effect of Piwil2-HSVtk and ganciclovir interplay, whereas no effect was noted in nonmalignant breast epithelial cells ( Supplementary Fig. S7 ). These preliminary results show that suicide gene therapy controlled by the 2-kb Piwil2 promoter can drive selective cytotoxicity in vitro against human breast cancer, profiling this approach as a promising tool for treatment of breast cancer, the second most common type of cancers.
In conclusion, our results show that Piwil2, as a novel CTA, is expressed predominantly in breast cancer stem cells modulating their proliferation and antiapoptotic state through the Stat3/Bcl-X L signaling pathway, hence introducing it as a highly promising factor for its application in diagnostic and therapeutic purposes.
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